EyePoint, Inc. faced a sharp stock price drop after two Phase 3 clinical trials for its wet age-related macular degeneration (wet AMD) treatment, Duravyu, failed to meet primary efficacy endpoints. The first trial's results were announced in August 2026, causing a 67% stock fall, and the second trial's failure in October led to an 85% drop. Following these setbacks, EyePoint cut costs significantly, including terminating its wet AMD program and reducing its workforce by 53%. Pomerantz LLP is investigating claims of securities fraud against EyePoint and its executives on behalf of investors affected by these developments.
EyePoint, Inc. is the subject of an investor alert as of Nov 04, 2026 05:12 WIB. For readers following the health sector, here is Pluang's market snapshot: of 150 priced health-sector US stocks tradable on Pluang, 89 rose and 58 fell today. Notable movers include DNA (Ginkgo Bioworks Holdings Inc) at USD 10.74 with a 9.04% increase, TWST (Twist Bioscience Corp) at USD 140.31 with an 8.73% increase, and ABCL (AbCellera Biologics Inc) at USD 12.08 with an 8.63% increase, with ABCL showing a full 100% buy order activity on Pluang.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
